A first-in-class biotherapeutic
PB01 is recombinant human follistatin-288, the most potent form of follistatin. It is a novel biological molecule with strong anti-inflammatory and anti-fibrotic actions. PB01 binds to and neutralises the activity of the TGFβ superfamily of growth and differentiation cytokines, most notably the activin family, thereby inhibiting the production of proinflammatory cytokines.
Paranta is developing PB01 for therapeutic use in the treatment of cystic fibrosis (CF) lung disease and diabetic kidney disease.Read More
Paranta is focused on developing PB01 for the treatment of cystic fibrosis lung disease, chronic kidney disease.
Paranta has a patent portfolio including 32 granted patents in the USA, Europe, Canada and Australia. The Company also has 13 additional patent applications filed in the same countries.